The American Journal of Medicine
Volume 123, Issue 1 , Pages 47-53 , January 2010

Recurrent Community-acquired Pneumonia in Patients Starting Acid-suppressing Drugs

  • Dean T. Eurich, PhD

      Affiliations

    • Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, Alberta, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Dean T. Eurich, PhD, School of Public Health, University of Alberta, 13-103 Clinical Sciences Bldg., Edmonton, Alberta T6G 2G3, Canada
    • ,
  • Cheryl A. Sadowski, PharmD

      Affiliations

    • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Scot H. Simpson, PharmD

      Affiliations

    • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Thomas J. Marrie, MD

      Affiliations

    • Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Sumit R. Majumdar, MD, MPH

      Affiliations

    • Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, Alberta, Canada
    • Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

  • Image Result

    Cumulative incidence for community-acquired pneumonia readmission according to acid-suppressing drug use.

    Cumulative incidence for community-acquired pneumonia readmission according to acid-suppressing drug use.

  • Image Result

    Risk of recurrent community-acquired pneumonia associated with exposure to acid-suppressing drug use. Conditional logistic regression analyses. Note nonusers of proton pump inhibitors/H2-receptor anta

    Risk of recurrent community-acquired pneumonia associated with exposure to acid-suppressing drug use. Conditional logistic regression analyses. Note nonusers of proton pump inhibitors/H2-receptor antagonists (PPI/H2s) reference category for all comparisons.

 Funding: An establishment grant from the Alberta Heritage Foundation for Medical Research; grants-in-aid from Capital Health; and unrestricted grants from Abbott Canada, Pfizer Canada, and Janssen-Ortho Canada (all to TJM). DTE and SRM receive salary support awards from the Alberta Heritage Foundation for Medical Research, and DTE and SHS receive salary support from the Canadian Institutes of Health Research.

 Conflict of Interest: All authors have no association that might pose a conflict of interest (eg, pharmaceutical stock ownership, consultancy, advisory board membership, relevant patents, or research funding).

 Authorship: As authors we have all participated in the conduct of the analysis and writing of this manuscript, and all authors have met the criteria for authorship.

PII: S0002-9343(09)00863-8

doi: 10.1016/j.amjmed.2009.05.032

The American Journal of Medicine
Volume 123, Issue 1 , Pages 47-53 , January 2010

Article Tools

* Image Usage & Resolution